Article

Chemokine Receptor Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related Mechanism In Vitro

2020-06-03

Abstract excerpt

Coronavirus disease (COVID-19) accompanies severe immune injury as well as a decrease and overactivation of T lymphocytes. We observed that vMIP-Ⅱ, a broad-spectrum chemokine receptor inhibitor, could improve the lymphocyte decrease of COVID-19. Comparisons of T cell populations in PBMCs showed that the effects of vMIP-II on the subsets of T cells and cytokine secretion stimulated by SARS-CoV-2 S protein were the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3fd80a41-a563-5aca-922a-406534c61273
DOI: 10.21203/rs.3.rs-33165/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Chemokine Receptor Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related Mechanism In VitroDOI 10.21203/rs.3.rs-33165/v1Read

Chemokine Receptor Inhibitor vMIP-II Promoting Lymphocytes in COVID-19 Patients and Its Related Mechanism In VitroSemantic proximity Read

Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19.Semantic proximity Read

Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19Semantic proximity Read

Regulatory CD4+ and CD8+ T cells are negatively correlated with CD4+/CD8+ T cell ratios in patients acutely infected with SARS-CoV-2Semantic proximity Read

Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory SoupSemantic proximity Read

Combating COVID-19 with mesenchymal stem cell therapySemantic proximity Read

Macrophage-Derived Chemokine MDC/CCL22: An Ambiguous Finding in COVID-19Semantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir vs Currently Used Therapy in Severe COVID-19 Adults. “COMVIVIR” Trial.Semantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity Read

Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7Semantic proximity Read

MDSCs IN COVID-19 Why should we care?Semantic proximity Read

Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19Semantic proximity Read